Malignant neoplasm of lateral wall of bladder
ICD-10 C67.2 is a billable code used to indicate a diagnosis of malignant neoplasm of lateral wall of bladder.
C67.2 refers to a malignant neoplasm located specifically in the lateral wall of the bladder. This type of cancer arises from the transitional epithelium that lines the bladder and is characterized by uncontrolled cell growth. The lateral wall of the bladder is a common site for bladder tumors, which can present with symptoms such as hematuria (blood in urine), dysuria (painful urination), and increased urinary frequency. Diagnosis typically involves imaging studies such as ultrasound or CT scans, followed by cystoscopy for direct visualization and biopsy. Staging of bladder cancer is crucial for determining the extent of the disease and guiding treatment options. The most commonly used staging system is the TNM classification, which assesses tumor size (T), lymph node involvement (N), and distant metastasis (M). Surgical management may include transurethral resection of the bladder tumor (TURBT) for superficial tumors, or radical cystectomy for muscle-invasive disease. Adjuvant therapies, such as chemotherapy or immunotherapy, may also be indicated based on the stage and grade of the tumor.
Complete surgical notes, pathology reports, imaging studies, and treatment plans.
Diagnosis and management of bladder tumors, staging evaluations, and post-operative follow-ups.
Ensure accurate documentation of tumor size, grade, and staging to support coding.
Detailed treatment plans, chemotherapy administration records, and follow-up assessments.
Management of advanced bladder cancer, chemotherapy regimens, and palliative care.
Document all treatment modalities and responses to therapy for accurate coding.
Used for diagnosis of bladder tumors.
Document indications for the procedure and findings.
Urologists must ensure accurate reporting of biopsy results.
Performed for muscle-invasive bladder cancer.
Complete operative report detailing the procedure.
Oncologists should document any adjuvant therapies planned.
Staging is crucial as it determines the extent of the disease, guides treatment decisions, and helps predict patient outcomes.
Histological examination of biopsy samples is essential for differentiation, as benign tumors do not exhibit the same invasive characteristics as malignant ones.
